• B.Sandhya Department of Biotechnology, Acharya Nagarjuna University, Nagarjunanagar – 522 510, Guntur, A.P., India
  • Prof. M.V Raghavendra Rao Avalon University School of Medicine, Curacao, Netherland Antilles.
  • M. Raghu Ram Department of Biotechnology, Acharya Nagarjuna University, Nagarjunanagar – 522 510, Guntur, A.P., India
  • Sireesha Bala.A Avalon University School of Medicine, Curacao, Netherland Antilles
  • Samir Fatteh Avalon University School of Medicine, Curacao, Netherland Antilles.
  • Reshma Fateh Avalon University School of Medicine, Curacao, Netherland Antilles.


Testosterone, Diabetes, Hypogonadism


The testosterone therapy in male patients has become clinical interest now days. Although there are a number of potential benefits of male testosterone replacement therapy, but yet there have not been any controlled trials of this therapy for type-2 diabetes. In present study we investigate the effect of testosterone replacement therapy by discussing a limited number of trials initially. The study was carried out with 70 hypogonadic patients at the age of 40 to 60 years selected from Life hospital situated in Guntur. Patients with the serum levels <200ng/dl were given 80mg Andriol orally and to patients with testosterone >200ng/dl were given 40mg/day was administered orally for 6 months to the male patients. The biochemical test and level of hormonal in blood was tested before the treatment, after three months and six months of the treatment.   Initially the average testosterone level  (204 ng/dl) were increased approximately two times (452 ng/dl) after six months of treatment. Hence, we found that testosterone therapy fasting blood glucose, postprandial glucose and glycosylated hemoglobin (HB1AC) reduced significantly. Therefore, the testosterone replacement therapy might have the beneficial effects on treating type-2 diabetes.


I. Allan CA, Forbes EA, Strauss BJ, Mc Lachlan RI. Testosterone therapy increases sexual desire in ageing men with normal testosterone levels and symptoms of androgen deficiency. Int J Impot Res 2008a; 20: 396-401.

II. Allan CA, Strauss BJ, Burger HG, Forbe EA, Mc Lachlan RI. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in non obese aging men. J Clin Enocrinol Metab. 2008b; 93:139-146.

III. Anderson B, Marin P, Lissner L. Testosterone concentrations in women and men with NIDDM, Diabetes Care, 1994;17:405-411.

IV. Barrett-Connor E, Khaw KT, Yen SS. Endogenous sex hormone levels in older adult men with diabetes mellitus. Am J Epidemiol 1990; 132: 895 – 901.

V. Bhasin S, Storer T, Berman N. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997; 82:407-413.

VI. Bhasin S, Storer TW, Berman N. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996; 335:1-7.

VII. Bhasin S, Woodhouse L, Storer TW. Proof of the effect of testosterone on skeletal muscle. J Endocrinol. 2001; 170: 27-38.

VIII. Boyanov MA, Boneva Z & Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003; 6: 1–7.

IX. Chaoyang Li, Earl S Ford, Benyl L, Wayne H, Giles et al., Testosterone and sex hormone-binding globulin with metabolic syndrome and insulin resistance in men. Diabetes Care. 2010; 33:1618-1624.

X. Corona G, Monami M, Rastrelli G, et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl. 2011; 34: 528-540.

XI. Dhindsa S, Dandona P. Update: Hypogonaotropic hypogonadism in type 2 diabetes and obesity. 2011; 96(9): 2643

XII. Gary A, Berlin JA, McKinley J. An Examination of research design effects on the association of testosterone and male ageing: Results of a Meta analysis. J Clin Endocrinol Metab 1994; 44: 671-684.

XIII. Grossmann M, Thomas MC, Panagiotopoulos S, et al. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab. 2008; 93:1834–1840.

XIV. Gustafson DR, Karlsson C, Skoog I, Rosengren L, Lissner L & Blennow K Mid-life adiposity factors relate to blood-brain barrier integrity in late life. J Intern Med 2007; 262: 643–650.

XV. Harman SM, Metler EJ, Tobin JD, Pearson J, Blackman Mr. Longitudinal effects of ageing on serum total and free testosterone levels in healthy men. Baltimore longitudinal study of ageing. J Clin Endocrinol Metab 2001; 86:724-731.

XVI. Haffner SM et al., Decreased sex hormone-binding globulin predicts noninsulin-dependent diabetes mellitus in women but not in men. J Clin Endocrinol Metab 1993; 77: 56 – 60.

XVII. Haffner SM, Shaten J, Stern MP, Smith GD, Kuller L. Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. Mr. Fit research group. Multiple risk factor intervention trial. Am J Epidemiol 1996; 143: 889-897.

XVIII. Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 2009; 30: 726–733.

XIX. Holmang A, Bjorntorp P. The effects of testosterone on insulin sensitivity in male rats. Acta Physiol Scand. 1992; 146: 505-510.

XX. Hutley L & Prins JB. Fat as an endocrine organ: relationship to the metabolic syndrome. Am J Med Sci 2005; 330: 280 – 289.

XXI. Jones Hugh T, Arver Stephen, Hermann M, Jacques B, Meuleman E, Antonio MM. Testosterone replacement in hypogonadal men with type2 diabetes and/ or metabolic syndrome (the TIMES 2 study). Diabetes Care 2011; 34: 828-837.

XXII. Jones TH. Testosterone deficiency: a risk factor for cardiovascular disease? Trends Endocrinol Metab 2010; 21: 496–503.

XXIII. Kapoor D, Malkin CJ, Channer KS, Jones TH. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf) 2005; 63: 239-250.

XXIV. Marin P, Holmang S, Johnson L, Sjostrom L, Kvist H, Holm G et al., The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord 1992; 16: 991-997

XXV. Mohr BA, Bhasin S, Link CL. The Effect of changes in adiposity on testosterone levels in older men: longitudinal results from the Massachusetts male aging study. Eur J Endocrinol 2006; 155: 443-452.

XXVI. Nieschlag E, Swerdloff R, Behre HM. Investigation, treatment and monitoring of late –onset hypogonadism in males: ISA, ISSAM and EAU Recommendations, J Androl, 2006; 27:135-7.

XXVII. Osuna JA, Gomez Perez R, Arata Bellabarba G, Villaroel V. Relationship between BMI, total testosterone, sex hormone binding globulin, leptin, insulin and insulin resistance in obese men. Arch Androl 2006; 52: 355-361.

XXVIII. Pagotto U, Gambineri A, Pelusi C. Testosterone replacement therapy restores normal ghrelin in hypogonadal men. J Clin Endocrinol Metab. 2003; 88: 4139-4143.

XXIX. Phillips LK & Prins JB. The link between abdominal obesity and the metabolic syndrome. Curr Hypertens Rep 2008; 10: 156–164.

XXX. Schneider G, Kirschner MA, Berkowitz R, Ertel NH. Increased estrogen production in obese men. J Clin Endocrinol Metab 1979; 48: 633 – 638.

XXXI. Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin S. Androgens stimulate myogenic differentiation and inhibit adipogenesis in c3h 10t1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology. 2003; 144: 5081-5088.

XXXII. Stanworth RD, Jones TH. Testosterone in obesity, metabolic syndrome and type 2 diabetes. Front Horm Res 2009; 37: 74-90.

XXXIII. Stefanik ML, Williams PT, Krauss RM. Relationships of plasma estradiol, testosterone and sex hormone binding globulin with lipoproteins, apolipoproteins and high density lipoprotein sub fractions in men. J Clin Endocrinol Metab 1987; 64: 723-729.

XXXIV. Svartbeg J, Jenssen T, Sundsford J, Jorde R. The associations of endogenous testosterone and sex hormone binding globulin with glycosylated hemoglobin levels in community dwelling men. The tromso study. Diabetes Metab 2004; 30: 29-34.

XXXV. Traish AM, Guay A, Feeley R, Saad F. The dark side of testosterone deficiency , I: Metaboloc syndrome and erectile dysfunction. J Androl. 2009; 30(1): 10-22.

XXXVI. Vikan T, Schirmer H, Njolstad I, Svartberg J. Low testosterone and sex hormone binding globulin levels and high estradiol levels are independent predictors of type 2 diabetes in men. Eur J Endocrinol. 2010; 162: 747-754.

XXXVII. Vermeulen A. Androgen replacement therapy in aging male-a critical evaluation. J Clin Endocrinol Metab 2001; 86: 2380-2390.

XXXVIII. Wang C, Swerdloff RS, Iranmanesh A. Transdermal testosterone replacement gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000; 85: 2839-2853.

XXXIX. Zitzman M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab. 2006; 9: 4335-4343.

XL. Zumoff B, Miller LK. Partial reversal of the hypogonadotropic hypogonadism of obese men by

XLI. administration of corticosupressive doses of dexamethasone. Int J Obes 1988; 12: 525-531.

Additional Files



How to Cite

B.Sandhya, Prof. M.V Raghavendra Rao, M. Raghu Ram, Sireesha Bala.A, Samir Fatteh, & Reshma Fateh. (2017). SERUM TESTOSTERONE LEVELS AND ITS IMPACT ON DIABETIC PATIENTS. International Education and Research Journal (IERJ), 3(7). Retrieved from